ClinicalTrials.gg
RecruitingNCT06153056PREDISLEGEUpdated Jan 21, 2026

Identification of Factors Predictive of the Efficacy of Endoscopic Endoscopic Sleeve Gastroplasty

An observational study in Obesity, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
205
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris — 16 open to participants now, 16 under way, 1 of them phase 3. Obesity · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
7th of 20
205 · median 175
Started
2025
with 5 others
Observational
20 of 58
6 open now
Primary completion
2031-02
later than 15 of 15 live
Registered
50th of 58
by date

Among the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris, this one is the 7th largest by planned enrollment of the 20 observational ones that give a count, is one of 6 that started in 2025, is one of 20 observational ones, reaches primary completion later than 15 of the 15 other live ones, and was the 50th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

16 of the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Endoscopic sleeve gastroplasty and bypass are currently available for weight loss in obese patients who have failed nutritional management. Despite very low risks, these techniques remain invasive. What's more, the French National Authority for Health recommends this procedure for patients with a BMI above 35 kg/m² with associated co-morbidities, or above 40 kg/m². This excludes grade I obese patients (30 \< BMI \< 35) who have no effective means of losing weight. The hospital's hepato-gastroenterology and nutrition department has therefore implemented endoscopic sleeve gastroplasty to address this problem. As with other surgical techniques, there is heterogeneity heterogeneity in weight loss. The investigators therefore aim to identify factors predictive of the efficacy of this procedure in order to improve patient management of patients.

Read the detailed description

The prevalence of obesity is increasing worldwide, and it is estimated that one quarter of the world's population will be overweight or obese by 2045. Obesity can lead to complications, including cardiovascular damage (myocardial ischemia and stroke), liver damage (non-alcoholic steatohepatitis and liver cancer), diabetes and extra-hepatic cancers. In this context, achievement of a significant long-term weight loss is of paramount importance to ameliorate patient outcome. Bariatric surgery is the most effective treatment for severe obesity and results in a significant long-term weight loss. However, bariatric surgery is restricted to patients with a BMI >40 kg/m2 or >35 kg/m2 with commodities (hypertension, diabetes, sleep apnoea, NASH). Therefore, the majority of obese patients do not benefit from this procedure. Recent advances in flexible endoluminal endoscopy now provide the tools for transoral endoscopic gastric volume reduction (ESG, endoscopic sleeve gastroplasty).

The gastric body is reduced by an endoscopic procedure involving suture plications. This minimally invasive method may be a good therapeutic option to obtain a significant weight reduction in patients with moderate obesity or those with severe obesity and no indication for bariatric surgery (BMI between 35 and 40 kg/m2 without commodities). In this context this study aims to identify predictive factors of weight loss following ESG and explore changes of metabolic parameters, metabolomic profiles and gut microbiota profiles. This is a retro-prospective cohort study including patients with moderate obesity undergoing ECG between March 2017 and September 2023. Clinical parameters (weight, high, BMI, weight fluctuations), serum metabolic parameters (standard lipid profile, lipoprotein levels, fasting plasma glucose, insulin levels, C-peptide levels, hemoglobin A1c) and liver function test parameters (standard biology, transient elastometry, Fibrotest®, Actitest®, abdominal ultrasound) are systematically collected for all patients before ESG and then at three- and twelve-month post-ESG. Samples of serum, plasma, stools and saliva are also systematically collected for research purpose before ESG and then at three- and twelve-month post-ESG. Each sample is stored at -80°C for subsequent analysis. Metabolomic/lipidomic analysis will be used to quantify metabolite and lipid species in serum/plasma samples. Metagenomic analysis will be used to characterise faecal and salivary microbiota profiles.

03

Conditions studied

  • Obesity

Keywords

  • Obesity
  • Endoscopic sleeve gastroplasty
  • Weight loss
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Major grade I obese patients (BMI between 30 and 35 kg/m²) not eligible for sleeve gastrectomy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient of legal age (Age ≥ 18 years)
  • Patient capable of understanding the study and signing a consent.
  • between 30 and 35 kg/m² with the presence of at least one one obesity-related complication (diabetes, dyslipidemia, sleep apnea syndrome, non-alcoholic steatohepatitis, joint pain joint pain).
  • Patients with a BMI greater than 35 kg/m² who have been bariatric surgery has been refused.
  • Patient who has failed to lose weight and improve with conventional techniques.
  • Patient affiliated to a social security scheme

Exclusion criteria

Exclusion Criteria:

  • Patient having taken antibiotics 3 months prior to inclusion.
  • Patient under legal protection.
  • Patient at risk of gastric cancer requiring regular endoscopic surveillance: extensive intestinal atrophy and/or metaplasia on .
  • Patient with a history of gastrointestinal inflammatory disease of gastric localization, hepatic or renal insufficiency, portal hypertension.
  • Patient with evidence of peptic ulcer disease and/or progressive peptic ulcer disease.
  • Patient with pathology affecting general health health and/or .
  • Patient with a history of bariatric surgery.
  • Patient on AME
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
205 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Interventions

  • Diagnostic testBloed-, ontlasting- en speekselmonsters

    In addition, the blood collected (24 mL) will be used for the following analyses: GLP-1, PYY, branched-chain amino acids, Adipokines, leptin, adiponectin Blood bile acid levels: total and detailed analyzed by HPLC MS/MS Serum microbiome profile Genome-wide association study. The stool sample will be used to establish the : Intestinal bile acid profile Intestinal microbiota profile Saliva sampling for oral microbiota profiling.

06

What researchers measure

Primary outcomes

  1. Serum metabolite profile using widely targeted metabolomics according to weigh loss amount (less than 10% of total weight versus more than 10% of total weight loss at 12 months post-surgery)

    A volume of 50 µl of serum/plasma will be used for analysis of serum metabolites using widely targeted metabolomics mass spectrometry.

    Time frame: Before endoscopic sleeve gastroplasty

Secondary outcomes

  1. Clinical parameters at baseline and then at 3 and 12 month post-intervention.

    Weight expressed in kg, percentage of total weight loss and percentage of excessed weight loss will be analysed as they are systematically available in usual clinical practice.

    Time frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12

  2. Basic serum lipid profile at baseline and then at 3 and 12 month post-intervention.

    Basic serum lipid profile will be analysed by spectrometry as they are systematically available in usual clinical practice.

    Time frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12

  3. Glycated hemoglobin at baseline and then at 3 and 12 month post-intervention.

    Glycated hemoglobin expressed in % will be analysed as they are systematically available in usual clinical practice.

    Time frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12

  4. Insulin at baseline and then at 3 and 12 month post-intervention.

    Insulin expressed in mUI/l will be analysed as it is systematically available in usual clinical practice.

    Time frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12

  5. C peptide at baseline and then at 3 and 12 month post-intervention.

    C peptide expressed in µg/l will be analysed as it is systematically available in usual clinical practice.

    Time frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12

  6. Ferritin at baseline and then at 3 and 12 month post-intervention.

    Ferritin expressed in µg/l will be analysed as it is systematically available in usual clinical practice.

    Time frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12

  7. Liver function test parameter Alanine transaminase (ALT) at baseline and then at 3 and 12 month post-intervention.

    ALT levels expressed in IU/l will be analysed as they are systematically available in usual clinical practice.

    Time frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12

  8. Liver function test parameter aspartate transaminase (AST) at baseline and then at 3 and 12 month post-intervention.

    AST levels expressed in IU/l will be analysed as they are systematically available in usual clinical practice.

    Time frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12

  9. Liver function test parameter Gamma-glutamyltransferase (GGT) at baseline and then at 3 and 12 month post-intervention.

    GGT levels expressed in IU/l will be analysed as they are systematically available in usual clinical practice.

    Time frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12

  10. Liver function test parameter Alkaline phosphatase (ALP) at baseline and then at 3 and 12 month post-intervention.

    ALP levels expressed in IU/l will be analysed as they are systematically available in usual clinical practice.

    Time frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12

  11. Liver fibrosis assessed by transient elastometry at baseline and then at 3 and 12 month post-intervention

    Transient elastometry expressed in kPa will be analysed as they are systematically available in usual clinical practice.

    Time frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12

  12. Liver steatosis assessed by controlled attenuation parameter (CAP) at baseline and then at 3 and 12 month post-intervention.

    Controlled attenuation parameter expressed in dB/m will be analysed as they are systematically available in usual clinical practice.

    Time frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12

  13. Serum metabolites using widely targeted metabolomics at baseline and then at 3 and 12 month post-intervention.

    A volume of 50 µl of serum/plasma will be used for analysis of serum metabolites using widely targeted metabolomics by mass spectrometry

    Time frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12

  14. Complications of endoscopic sleeve gastroplasty

    Data on the potential complications (occurrence of perforation, bleeding, peritonitis and other infections, thrombo-embolic events and death) of endoscopic sleeve gastroplasty will be collected.

    Time frame: During the first week post-endoscopic sleeve gastroplasty and at Month 3 and Month 12

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Feb 2031, 64 months after the start.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 64 months is above that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2023
First posted
Dec 1, 2023
StartActual
Sep 9, 2025
Primary completionEst.
Feb 2, 2031
CompletionEst.
Feb 2, 2031
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06153056
Responsible party
Sponsor
First posted
Dec 1, 2023
Start date
Sep 9, 2025
Primary completion
Feb 2, 2031 (estimated)
Completion
Feb 2, 2031 (estimated)
Last update
Jan 21, 2026

Study contacts

Cosmin VOICAN, MD, PhD
Contact
cosmin.voican@aphp.fr
1 45 37 47 75 ext. +33
Gabriel PERLEMUTER, MD, PhD
Contact
gabriel.perlemuter@aphp.fr
1 45 37 47 75 ext. +33
Cosmin VOICAN, MD, PhD
principal investigator · APHP, Antoine-Béclère Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion